RE: Paul LOADMAN, Professor of Pharmacokinetics23 Mar 2024 12:30
Great sleuthing, does appear he's a very good asset to have with you at AACR. Let's hope Avacta have some side meetings lined up to discuss license options.
RE: Clarification of what "in parallel" meant in yesterday's RNS22 Mar 2024 16:56
As was mentioned yesterday it could be easier to recruit patients in the UK because of the NHS and because geographically the cancer centers being used cover the whole of England.